Results 161 to 170 of about 125,716 (297)

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

, 2006
Shiro Yokohama, Yoshihiko Tokusashi, Kimihide Nakamura, Yosui Tamaki, Satoshi Okamoto, Mituyoshi Okada, Kazunobu Aso, Takenao Hasegawa, Masaru Aoshima, Naoyuki Miyokawa, Masakazu Haneda, Masashi Yoneda   +11 more
openalex   +2 more sources

A Human-Type Nonalcoholic Steatohepatitis Model with Advanced Fibrosis in Rabbits [PDF]

, 2010
Tomohiro Ogawa, Hideki Fujii, Katsutoshi Yoshizato, Norifumi Kawada   +3 more
openalex   +1 more source

The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical‐Induced Murine MASH Model

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction‐associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non‐invasive biomarkers for tracking disease progression.
Szu‐Jen Wang, Yung‐Ho Wang, Jee‐Fu Huang, En‐Sheng Lin, Wei‐Shiun Chen, Chia‐Yang Li, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu, Shu‐Chi Wang   +9 more
wiley   +1 more source

Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease. [PDF]

World J Gastroenterol
Heymann G, Rahman S, Kats D, Banini BA, Gaddam S, Aslanian E, Boateng S, Israel G, Muniraj T.   +8 more
europepmc   +1 more source

Vitronectin deficiency attenuates hepatic fibrosis in a non‐alcoholic steatohepatitis‐induced mouse model

, 2019
Momoka Hayashida, Kei Hashimoto, Tomoko Ishikawa, Yasunori Miyamoto   +3 more
openalex   +2 more sources

Erratum: Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction [PDF]

, 2017
Tracey Simon, Daniel Bamira, Raymond Chung, Rory Weiner, Kathleen Corey   +4 more
openalex   +1 more source

Improvement of liver function and glycemic control with Combination of DPP-4 inhibitors and GLP-1 agonists in type II diabetes mellitus patients with non-alcoholic steatohepatitis [PDF]

, 2020
Alexander Myint
openalex   +1 more source

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

The Lancet, 2016
M. Armstrong, P. Gaunt, G. Aithal, D. Barton, D. Hull, R. Parker, J. Hazlehurst, K. Guo, G. Abouda, M. Aldersley, Deborah D. Stocken, S. Gough, J. Tomlinson, Rachel M. Brown, S. Hübscher, P. Newsome   +15 more
semanticscholar   +1 more source

RTA‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the
Hung‐Pei Tsai, Hao Qin, Yoon Bin Chong, I‐Hsiang Chen, Shih‐Hsun Kuo, Tzu‐Ting Tseng, Ann‐Shung Lieu   +6 more
wiley   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis. [PDF]

Syst Rev
Wang MJ, Jiang YN, Li PP, Wu YJ.
europepmc   +1 more source